EvexiTHROID 9.5 ug/1
LEVOTHYROXINE and LIOTHYRONINE · TABLET · Trifluent Pharma, LLC
EvexiTHROID is a tablet containing levothyroxine and liothyronine at 9.5 ug/1, taken oral. Manufactured by Trifluent Pharma, LLC.
Key Facts
- Brand Name
- EvexiTHROID
- Generic Name
- LEVOTHYROXINE and LIOTHYRONINE
- NDC Code (Product)
73352-693- Manufacturer
- Trifluent Pharma, LLC
- Strength
- 9.5 ug/1
- Dosage Form
- TABLET
- Route
- ORAL
- Marketing Status
- Drug Class
- l-Thyroxine [EPC]; l-Triiodothyronine [EPC]
- Marketing Start
- 10/12/2025
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATIONS AND USAGE EvexiTHROID (Thyroid Tablets, USP) are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer.
Dosage & Administration
DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels (see PRECAUTIONS ). Thyroid hormones are given orally. In acute, emergency conditions, injectable levothyroxine sodium (T4) may be given intravenously when oral administration is not feasible or desirable, as in the treatment of myxedema coma, or during total parenteral nutrition. Intramuscular administration is not advisable because of reported poor absorption. Hypothyroidism Therapy is usually instituted using low doses, with increments which depend on the cardiovascular status of the patient. The usual starting dose is 30 mg EvexiTHROID (Thyroid Tablets, USP), with increments of 15 mg every 2 to 3 weeks. A lower starting dosage, 15 mg/day, is recommended in patients with long-standing myxedema…
Warnings
WARNINGS Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective. Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism.
Contraindications
CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone.
Drug Interactions
Drug Interactions - Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy. Cholestyramine or Colestipol Cholestyramine or colestipol binds both levothyroxine (T4) and liothyronine (T3) in the int…
Adverse Reactions
ADVERSE REACTIONS Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare (See OVERDOSAGE ).
Frequently Asked Questions
What is EvexiTHROID used for?
EvexiTHROID contains LEVOTHYROXINE and LIOTHYRONINE. It is a tablet taken oral. Consult your doctor for specific uses.
Is EvexiTHROID a controlled substance?
EvexiTHROID is not classified as a controlled substance by the DEA.
What is the generic name for EvexiTHROID?
The generic name for EvexiTHROID is LEVOTHYROXINE and LIOTHYRONINE. There are 6 other brand versions of LEVOTHYROXINE and LIOTHYRONINE.
What is the NDC code for EvexiTHROID 9.5 ug/1?
The NDC (National Drug Code) for EvexiTHROID 9.5 ug/1 is 73352-693, listed by Trifluent Pharma, LLC.